Acsm's Resource Manual for Guidelines for Exercise Testing and Prescription

C Calcium channel blockers (dihydropyridines) 276 amlodipine (Norvasc) 276 felodipine (Plendil) 276 isradipine (DynaCirc CR) 276 nicardipine sustained release (Cardene SR) 276 nifedipine long acting (Adalat) 276 nifedipine long acting (Procardia XL) 276 nimodipine (Nimotop) 276 nisoldipine (Sular) 276 Calcium channel blockers (nondihydropyridines) 276 diltiazem extended release (Cardizem CD) 276 diltiazem extended release (Cardizem LA) 276 diltiazem extended release (Dilacor XR) 276 diltiazem extended release (T iazac) 276 verapamil Coer 24 (Covera HS) 276 verapamil Coer 24 (Verelan PM) 276 verapamil immediate release (Calan) 276 verapamil immediate release (Isoptin) 276 verapamil long acting (Calan SR) 276 verapamil long acting (Isoptin SR) 276 Cancer 228–232 exercise prescription 231–232 exercise testing 228–231 testing and training for patients with 229–230 Candesartan (Atacand) 278 Candesartan + hydrochlorothiazide (Atacand HCT) 278 Captopril (Capoten) 277 Captopril + hydrochlorothiazide (Capozide) 277 Cardiac arrest 297–299 Cardiac biomarkers for myocardial damage, serum 55 Cardiac complications during exercise testing 13 Cardiac death among young individuals, sudden 10–11 Cardiac disease, exercise prescription for patients with 207–224 exercise prescription without preliminary exercise test 218–219 exercise training for return to work 222 inpatient rehabilitation programs 207–211 frequency 210 intensity 210 progression 210–211 time (duration) 210 outpatient exercise programs 211–218 exercise prescription 212–216 exercise prescription - frequency 212 exercise prescription - intensity 213 exercise prescription - lifestyle physical activity 215–216 exercise prescription - time (duration) 213–215 exercise prescription - type 215 special considerations 216–218 special considerations - continuous electrocardiographic monitoring 217 special considerations - pacemaker/implantable cardioverter defibrillator implantation P.367 217–218 special considerations - patients after cardiac transplantation 218 special considerations - patients with sternotomy 216 types of 216 resistance training for cardiac patients 219–222 Cardiac disease, resistance training for patients with 219 Cardiac events in adults 11–12 during cardiac rehabilitation 12 exercise testing and risk of 12 prevention of exercise-related 12–15 Cardiac glycosides 277 digoxin (Lanoxin) 277 Cardiac patients American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) risk stratification criteria for 36–37 FITT framework for 214 resistance training for 219–222 risk stratification for 36–37 Cardiac rehabilitation contraindications for inpatient and outpatient 209 goals for outpatient 211 risks of cardiac events during 12 Cardiac rehabilitation program complication rates, exercise-based 14 Cardiac transplantation, patients after 218 Cardiorespiratory fitness 71–85 cardiorespiratory test sequence and measures 80–82 concept of maximal oxygen uptake 72–73 interpretation of results 84–85 maximal versus submaximal exercise testing 73–74 modes of testing 74–80 field tests 75 submaximal exercise tests 76–80 submaximal testing of 81 test termination criteria 82–83 Cardiorespiratory response to exercise testing 137–138 Cardiorespiratory test sequence and measures 80–82 Cardiovascular, pulmonary, and metabolic disease 25 26–27 Cardiovascular causes of exercise-related sudden death in young athletes 11 Cardiovascular disease (CVD) ACSM risk stratification categories for atherosclerotic 23 manifestations of atherosclerotic 208 pretest likelihood of atherosclerotic 106 relative risk of atherosclerotic 6 Cardiovascular disease (CVD) risk factor information, undisclosed or unavailable 23–25 Cardiovascular disease (CVD) risk factor thresholds, atherosclerotic 28 Cardiovascular disease (CVD) risk factors, atherosclerotic 25–30 Cardiovascular mortality, relationship between oxygen uptake and 110 Cardioverter defibrillator implantation, pacemaker/implantable 217–218 Cardura (Doxazosin) 275 Carvedilol (Coreg) 275 Central α2-agonists and other centrally acting drugs 275